Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FK 506: an update

G B Klintmalm1

  • 1Transplantation Services, Baylor University Medical Center, Dallas, Texas.

Clinical Transplantation
|April 1, 1994
PubMed
Summary

FK 506, a potent immunosuppressant, demonstrated comparable patient and graft survival rates to standard treatments in clinical trials. It showed a significant reduction in organ rejection episodes, particularly in pediatric patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First live birth after uterus transplantation in the United States.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2018
Same author

Live nondirected uterus donors: Psychological characteristics and motivation for donation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2018
Same author

Deceased donor uterus retrieval: A novel technique and workflow.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Living Donor Uterus Transplantation: A Single Center's Observations and Lessons Learned From Early Setbacks to Technical Success.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • FK 506, a metabolite from Streptomyces tsukubaensis, exhibits strong immunosuppressive properties.
  • Initial human trials in 1989 showed promise, leading to larger multicenter studies.

Purpose of the Study:

  • To evaluate the efficacy and safety of FK 506 in comparison to standard immunosuppressive regimens.
  • To assess patient and graft survival, rejection rates, and adverse events in transplant patients.

Main Methods:

  • A randomized trial comparing FK 506 plus corticosteroids to cyclosporine, azathioprine, and corticosteroids.
  • Patient and graft survival, rejection incidence, and need for rescue therapy were monitored.

Main Results:

  • One-year patient survival was 80% in both FK 506 and control groups; graft survival was 82% vs 79%.
  • FK 506 group had significantly fewer rejections (32% vs 24%) and lower rates of steroid-resistant rejection requiring OKT3 treatment (16% vs 29%).
  • Pediatric patients showed a pronounced benefit with FK 506, with 58% rejection-free at 6 months versus 28% in controls.

Conclusions:

  • FK 506 offers comparable survival outcomes to standard immunosuppression with a notable reduction in organ rejection.
  • While effective, FK 506 was associated with increased renal and neurotoxicity compared to the control group.
  • FK 506 has proven valuable for rescue therapy in treatment-resistant rejections, though further randomized trials are needed.

Related Experiment Videos